Box 1 provides a glossary of some of the terms used in this article. Corticosteroids comprise the glucocorticoid and mineralocorticoid hormones synthesised in the adrenal cortex and the drugs derived from them. Commonly prescribed corticosteroids are listed in Table 1 .
Corticosteroids have revolutionised the management of several disabling conditions and have saved many lives. However, they feature prominently in reviews of adverse drug reactions and suboptimal prescribing (Chyka 2000) . In the UK, it is estimated that more than 250,000 people are taking continuous oral corticosteroids (Walsh et al 1996) , and more than half of all children being treated for asthma in primary care are exposed to chronic high doses of corticosteroids via a combination of inhaler and intranasal devices (Ekins-Daukes et al 2002) .
Corticosteroid medications provide essential replacement therapy for disorders of the adrenal cortex. Addison's disease is controlled by low or 'physiological' doses of a glucocorticoid and a mineralocorticoid. Similar regimens are prescribed for some individuals with congenital adrenal hyperplasia. The adverse effects of corticosteroids should not be present at replacement doses, however all patients should be carefully monitored for adverse effects, as individual requirements can change and underor over-replacement can occur.
Corticosteroids suppress the immune system, inflammatory processes and hypersensitivity responses, and provide symptom relief in many acute and chronic conditions, including asthma and ulcerative colitis (Table 2 ). The doses prescribed for these conditions are often higher than in replacement regimens. At these 'pharmacological' doses, adverse effects are very likely and careful monitoring is required.
Pharmacology but does not abolish, systemic absorption and the associated adverse effects. Systemic administration Orally administered corticosteroids pass to the liver, where they are extensively metabolised into active and inactive metabolites, which then pass into the general circulation. When drugs are administered by other routes they bypass the liver and are not metabolised, which may enhance their potency. In medical emergencies, high plasma concentrations of corticosteroids are rapidly achieved by intravenous administration.
Intramuscular injection carries a risk of muscle atrophy, which is minimised by administration deep into the gluteal muscle (McKenry and Salerno 1998) . The deltoid muscle is too small for steroid injections (Fowler 1998) . Intramuscular injections are inadvisable for children, older people, patients with low muscle mass and those with purpura due to thrombocytopenia. Care of the injection site is essential, as steroid injections are associated with swelling, tingling, numbness, pain and sterile abscess (McKenry and Salerno 1998) . Each injection site should be used only once and documented, as repeated injections may cause scarring, induration, necrosis and tissue atrophy (Fowler 1998) .
Inhaled corticosteroids
The type of inhaler device used may alter drug absorption by up to 500 per cent (Wilson et al 1999) . Therefore, a change in inhaler, including switching from chlorofluorocarbon propellants to the more environmentally friendly hydroalkanes, requires careful patient monitoring. Spacers and dry powder devices have higher rates of drug delivery than other devices. However, patients with reduced inspiratory function, young children and people with severe lung disease may be unable to activate dry powder inhalers (Cave et al 1999) .
Sixty per cent of children using corticosteroid inhalers report at least one local adverse effect, most commonly cough on inhalation, thirst, hoarseness, speech difficulty or oral candidiasis (Dubus et al 2001) . Fluticasone propionate has a greater potential for local adverse effects (Adams et al 2002) and accumulation (Cave et al 1999) than other inhaled corticosteroids. Systemic adverse effects are unlikely with doses equivalent to beclomethasone below 800µg in adults and 400µg in children (Lipworth and Wilson 2002) . Rinsing the mouth and expectorating reduces the quantity of beclomethasone (but not budesonide or fluticasone) absorbed into the general circulation (Toogood 1998) . Patients may need reminding that inhaled corticosteroids improve asthma symptoms only after three to seven Reflect on the last time you cared for a patient receiving intramuscular corticosteroid injections. Did you have a system of recording injection sites? How could this be useful?
TIME OUT 1
Addison's disease A condition due to deficiency of hormones of the adrenal cortex. This arises when the adrenal cortex is destroyed by autoimmune processes or infection (eg, tuberculosis, HIV) Congenital adrenal hyperplasia A group of congenital disorders in which the synthesis of adrenal steroid hormones is dysregulated. Over-production of androgens may occur Cortisol The main glucocorticoid hormone secreted by the adrenal glands. Hydrocortisone is the synthetic form Dyslipidaemia Abnormal lipid profile, usually an excess of cholesterol, fatty acids or triglycerides. This is a risk factor for cardiovascular disease Endogenous Produced within the body, rather than administered as a medication Fibroblasts Cells that synthesise collagen and the ground substance of connective tissues Hirsutism Abnormal hair growth Hippocampus Part of the limbic system of the brain associated with memory, spatial orientation and emotional responses Hypokalaemia Abnormally low potassium concentration in the blood (<3.5mmol/l) Macrophages Large white blood cells that can ingest debris and bacteria. Essential for immunity Neutrophils Small white blood cells that act as the body's first line of defence against infection, but also cause inflammation Osteoblasts Cells that synthesise new bone throughout life Osteonecrosis or avascular necrosis A bone disorder in which blood supply to the bone decreases, resulting in bone death Parathyroid hormone A hormone that increases plasma calcium concentration by absorbing calcium from bone, gut and urine Polycythaemia Abnormally high concentration of red blood cells (haemoglobin concentration >20g/dl) Striae Skin defects that look like red lines, associated with rapid growth, for example, during pregnancy or steroid medication Systemic Pertaining to the whole body. Systemic administration allows the drug to pass to the entire body; it includes the oral, intravenous and intramuscular routes Telangiectases Red spots on the skin, which form as capillaries or small arteries dilate Thrombocytopenia Abnormally low number of platelets in the blood (<130 x 10 9 /l) Ulcerative colitis A chronic, episodic inflammatory disease of the large intestine and rectum (BNF 2002 , Cave et al 1999 , Karch 2000 , Lipworth 1999 
Box 1. Glossary

Oral corticosteroids
Pharmacology days, and are useful only as prophylaxis (BNF 2002) . Topical corticosteroids These are applied to treat inflammatory skin conditions and are available in many forms, such as lotions, creams, ointments and solutions. For example, 1% and 0.1% hydrocortisone creams are used to relieve symptoms of pruritus, nappy rash and eczema. Some preparations contain other active ingredients or additives, which may induce hypersensitivity responses, for example antimicrobials and wool fat. Systemic absorption of topical corticosteroids is increased if the skin is thin, broken or inflamed, and if an occlusive dressing is applied. Tight fitting nappies act as occlusive dressings and should not be placed over topical corticosteroids. Rapid absorption occurs in babies and children, and through mucous membranes or eyelids. Systemic adverse effects are likely when potent corticosteroids (for example, betamethasone 0.1%, clobetasol propionate 0.05%) are applied to extensive areas of skin for prolonged periods (ABN 2000) .
Systemic absorption following rectal administration can be erratic. For example, if the rectum is inflamed, absorption increases from 20 per cent to 50 per cent (McKenry and Salerno 1998) . Distribution and elimination Corticosteroids are 90 per cent bound to plasma proteins. Liver enzymes metabolise corticosteroids into soluble forms, which can then be excreted by the kidneys. Adverse effects are more likely if the activity of liver enzymes is reduced
Condition Comments
Systemic therapy (BNF 2002 , RCOG 2002 Without corticosteroids, the body cannot resist the slightest stress or infection, and the chemical mediators released in the inflammatory response will cause a catastrophic fall in blood pressure (Schimmer and Parker 2001) . This is a constant danger in Addison's disease and adrenal suppression (see below). Corticosteroids control the immune response, metabolic pathways, fluid and electrolyte balance, the cardiovascular and central nervous systems. They have two groups of actions: I Glucocorticoid effects, including metabolic changes and anti-inflammatory actions.
I Mineralocorticoid effects -mainly retention of salt and water, together with loss of potassium and hydrogen ions. Some drugs, such as dexamethasone, have predominantly glucocorticoid actions, whereas others are predominantly mineralocorticoid. Many drugs, such as hydrocortisone, have both (Table 1) .
Corticosteroids act In view of the many potential adverse effects of corticosteroids (Figure 1 ), it is suggested that they offer little clinical benefit to children with mild symptoms of asthma and virally-induced wheezing (BaxterJones et al 2002) . They should be withheld until severity can be fully assessed (Helms 2000) , and only prescribed if beta 2 -agonists are needed for symptom relief more than once each day and a four-to six-week trial of cromoglycate prophylaxis fails, particularly in children aged under five years (BNF 2002) . Although problems can arise with any dose or route of administration, the incidence and severity of adverse effects increases with cumulative dose and drug potency (Walsh et al 2001) . Fluticasone propionate may cause more adverse effects than either beclomethasone or budesonide, even when increased potency is considered (Lipworth and Wilson 2002 (Neal 1997) . For example, a chest infection can rapidly develop into lobar pneumonia. Inhibition of fibroblasts impedes healing; wounds such as lower leg ulcers and pressure areas take longer to heal. Delayed or interrupted healing may be the only indication of wound infection. Where this occurs, specimens should be sent for microbiological investigation. Antimicrobial agents may be rendered ineffective, allowing resistant micro-organisms to emerge, therefore, appropriate antimicrobial therapy can only be determined by wound culture and sensitivity. Isolated reports suggest that retinol may restore wound healing capacity (Stockley 1999 ).
Vulnerability to infection increases the risk of dental caries. Patients using oral corticosteroids were found to have fewer teeth, in worse condition, than matched controls (Walsh et al 2001) .
Patients prescribed oral corticosteroids, either currently or in the past three months, should avoid contact with people who have measles, chickenpox or shingles. Because of the anti-inflammatory actions of corticosteroids, serious systemic illness may develop without the familiar rash. Where exposure has occurred, it is essential that medical staff are notified without delay, as the infection can be abated if immunoglobulins are administered within three days. Risks are lower with inhaled and topical corticosteroids (BNF 2002).
Metabolic disturbances Corticosteroids affect all
A high index of suspicion is needed if infections are to be detected in patients receiving pharmacological doses of corticosteroids and treated before they become serious. How would the knowledge that a patient was prescribed prednisolone 40mg/day influence your response to: I An older patient who refuses food or starts fingering his mouth? I A patient who declines to visit the dentist, saying that she has never needed to before? I An older patient who develops confusion over two to three days? I A lower leg ulcer that is gradually enlarging?
TIME OUT 3
Daily assessment of body temperature at 5-6pm could be useful to detect the first signs of infection, as pyrexia is most easily detected at this time of day. How could this be organised for patients in the community? How would you explain to patients the rationale for this?
TIME OUT 2
Live vaccines* should not be given to people with impaired immunity, including those receiving high-dose corticosteroids (10-15mg prednisolone/day or equivalent) and for at least three months after discontinuation (BNF 2002 , Stockley 1999 Rang et al 1995) Lower leg ulcer failing to heal Pharmacology the body's metabolic pathways. When the body is starving, endogenous corticosteroids increase the availability of glucose for the brain and heart, even at the cost of destroying other tissues, such as skin.
Corticosteroids elevate plasma glucose concentrations by preventing uptake and use of glucose in most tissues and aiding formation of new glucose from amino acids and glycerol in the liver (gluconeogenesis). The resulting hyperglycaemia stimulates insulin production and reduces the body's sensitivity to insulin, which is a risk factor for cardiovascular disease. Type 2 diabetes and even ketoacidosis can develop. Patients receiving oral corticosteroids, or more than 800µg inhaled corticosteroids per day, should be monitored for hyperglycaemia. Elevated glucose concentrations in secretions such as saliva or sweat may promote the growth of Candida species (thrush).
To supply amino acids for gluconeogenesis, corticosteroids increase protein breakdown and decrease protein synthesis in muscle, skin and bone. This delays wound healing and eventually causes skin and muscle atrophy. Protein breakdown reduces the collagen content of all tissues, making them more fragile. Skin, membranes, capillaries, tendons and bones are all vulnerable.
Corticosteroids adversely affect plasma lipid concentrations, which should be monitored. The liver produces more lipids, while the breakdown of fat in adipose tissue is enhanced. This elevates the plasma concentration of lipids, particularly cholesterol, fatty acids and triglycerides; fat embolus is a rare complication. Alternate-day therapy may ameliorate these problems (Sholter and Armstrong 2000) .
Corticosteroids redistribute carbohydrate, fat and protein reserves. Eventually this causes central obesity, with increased girth, 'moon face' and thin limbs. This central distribution of body fat may be due to increased insulin concentrations and is associated with an increased risk of cardiovascular disease (Despres et al 2001) . Corticosteroids increase appetite and promote weight gain, unless intake is monitored carefully. Appetite stimulation is often beneficial in palliative care (BNF 2002) . Skin Orally administered corticosteroids can adversely affect the skin. As protein is broken down, the skin thins and becomes vulnerable to shearing forces. Local infection cannot be 'walled off' and may spread rapidly because fibroblasts are inhibited. Patients with plaster casts, and those on skin traction or on bed rest are particularly vulnerable. Capillary walls become more fragile, so bruises, petechiae and blood blisters form readily. Extra care is needed when undertaking nursing care such as moving and handling, cannulation and venepuncture. Increased susceptibility to infections and sweating can cause or exacerbate acne.
Topical corticosteroids cause spread of infection, acne, dermal atrophy, depigmentation, perioral dermatitis, telangiectases and striae. Apart from spread of infection and acne, these may not be completely reversible (BNF 2002) . Perioral dermatitis has been reported in children receiving corticosteroids via face masks (Dubus et al 2001) . Ulcers, infected lesions and rosacea may be worsened (Shannon et al 1992) . When corticosteroids are withdrawn, pre-existing dermatological conditions, particularly psoriasis, may rebound. Gastrointestinal tract Increased protein breakdown thins the gut lining. This predisposes to indigestion, ulcerative oesophagitis, peptic ulceration and gastric bleeding, particularly if non-steroidal anti-inflammatory drugs or alcohol are also taken. Stools should be observed for signs of gastrointestinal bleeding, and samples may be required for faecal occult blood testing. Nausea, vomiting, anorexia, abdominal distension and pancreatitis are less common (Karch 2000) . As nausea is also a symptom of adrenal suppression, it is important that this is investigated, with a venous blood sample taken for electrolytes and glucose. Bone Corticosteroids can adversely affect bone growth and strength. Bone mineral density decreases as the cumulative dose of inhaled corticosteroids increases (Wong et al 2000) . Even at the lowest doses, corticosteroids alter bone metabolism, inhibit osteoblasts and upset the balance between bone formation and reabsorption. Corticosteroids also reduce absorption of calcium from the gut, and increase its excretion from the kidneys. The resulting hypocalcaemia increases parathyroid hormone secretion, which exacerbates osteoporosis and bone loss (Saeb-Parsy et al 1999) . Some bone loss reverses on discontinuation (Cave et al 1999) .
Corticosteroid users are vulnerable to fractures in vertebrae and long bones. In a UK primary care casecontrol study, the risk of hip fracture increased six fold with oral corticosteroids (n=1,101) (Walsh et al 2001) ; it doubled in a US survey of post-menopausal women (n=8,068) (Baltzan et al 1999) . Risk of vertebral fracture increased ten fold (Walsh et al 2001) .
For people using corticosteroids, there is little evidence that bisphosphonates either strengthen the femoral neck or reduce the incidence of fractures (Blair et al 2002) . However, strategies to minimise the risk of steroid-induced osteoporosis include:
Review the following pressure damage assessment tools: Pressure Sore Prediction Score (PSPS), Waterlow, Norton and Braden. Which of these incorporates questions on whether the patient is receiving corticosteroids? Have you used any wound assessment tools that include questions on corticosteroids?
TIME OUT 4
december 4/vol17/no12/2002 nursing standard 49 (Walsh et al 1996) . I Hormone replacement therapy for post-menopausal women (Lipworth 1999 , Toogood 1998 ). Osteonecrosis of the head of femur or humerus is a serious and irreversible adverse effect of high-dose therapy. Therefore, joint pain and stiffness in a patient prescribed corticosteroids should trigger urgent investigations. Tendon rupture is a rare adverse effect (BNF 2002) .
C O N T I N U I N G P R O F E S S I O N A L D E V E L O P M E N T
Permanent growth suppression rarely occurs with less than six months' treatment, but prolonged use of oral corticosteroids may reduce final height and delay puberty. However, untreated asthma or arthritis also impairs growth. Research on inhaled corticosteroids indicates that they may slow growth, but final adult height is not usually affected, unless high doses (for example, 1mg fluticasone propionate/day) are administered (Cave et al 1999 , Lipworth 1999 . Growth monitoring on centile charts is important for all children using any steroid preparation, as there is considerable individual variation in response (BNF 2002 , Toogood 1998 . Muscle Protein loss from skeletal muscles contributes to muscle wasting and weakness, which is reported by 60 per cent of users (Walsh et al 2001) . This cannot be remedied by increased protein intake, because corticosteroids inhibit protein synthesis (Neal 1997) . Muscles of the arm and thigh are particularly affected, making it difficult for some patients to climb stairs and get out of chairs. Myopathy, or muscle wasting, is particularly serious in older women, who already have low muscle mass.
Respiratory myopathy in patients with respiratory disorders further diminishes respiratory function; recovery may be slow or incomplete (Schimmer and Parker 2001) . Myopathy causes speech difficulty in 11 per cent of children using inhalers, particularly spacers or nebulisers (Dubus et al 2001) . Cardiovascular problems Long-term corticosteroids intensify coronary atherosclerosis. Much of the increased risk is due to dyslipidaemia, hyperglycaemia (see above) and hypertension.
Steroids increase sodium ion reabsorption in the kidneys, in exchange for potassium or hydrogen ions. This promotes fluid retention, weight gain, hypertension and congestive heart failure. Pulmonary oedema and hypokalaemia are of particular concern where corticosteroids are co-administered with beta 2 -agonists in the management of acute asthma (Jordan and White 2001a) . Twenty per cent of patients taking corticosteroids have hypertension (Sholter and Armstrong 2000) . Steroid-induced hypertension is attributable to: I Fluid retention. I Enhanced vascular responses to vasoconstrictors, particularly noradrenaline (norepinephrine). I Diminished responses to vasodilators, such as nitrates. This impairs the ability of the blood vessels to dilate in hot environments, predisposing users to hyperthermia. I Increased cardiac contractility. For most corticosteroids, restriction of dietary sodium reduces, but does not abolish, the rise in blood pressure. However, sodium restriction may have no effect on hypertension caused by drugs with no mineralocorticoid actions, such as dexamethasone.
Corticosteroids increase erythropoietin production, which stimulates red blood cell production. The resulting polycythaemia is responsible for the characteristic red face and the possible association with thromboembolism (BNF 2002) .
Prolonged exposure to corticosteroids causes loss of muscle protein and fibrosis of the heart muscle. Corticosteroids administered after myocardial infarction reduce healing; this increases infarct size and makes the heart wall vulnerable to rupture and aneurysm formation (Sholter and Armstrong 2000) . Central nervous system Euphoria, irrespective of the underlying disease severity, is the usual initial response to corticosteroids, sometimes accompanied by agitation, restlessness, insomnia, rapid speech or even mania. Steroid psychosis, with hallucinations, delusional beliefs, thought disorders and suicidal ideation, is relatively rare. Long-term therapy is associated with mood swings, depression and anxiety (Brown et al 1999) . Pre-existing mental illness may be aggravated (BNF 2002) . Corticosteroids are associated with cognitive impairment and deficits in verbal memory, possibly as a result of steroid-induced atrophy of the hippocampus and cerebral cortex. Even after long-term use, discontinuation of medication often reverses memory loss (Brown et al 1999) .
Corticosteroids lower the seizure threshold, worsening epilepsy and occasionally causing convulsions, particularly with intravenous administration. Eyes Seventy-five per cent of patients develop cataracts after several years of 15mg/day oral prednisolone (BNF 2002 Pharmacology in young people using licensed doses of inhaled corticosteroids (Cave et al 1999) . Glaucoma is a risk in susceptible people, particularly following application of eye drops (Lipworth 1999) . Reproduction Systemic therapy has been associated with hirsutism, amenorrhoea and impotence, as a result of inhibition of oestrogens and androgens (Hoffmeister and Tietze 2000) . Adrenal suppression and insufficiency This potentially life-threatening condition is due to disruption of the hypothalamic/pituitary/adrenal (HPA) axis, which normally controls the production of steroids from the adrenal glands (Figure 2) . The hypothalamus secretes corticotrophin-releasing hormone (CRH), which stimulates the anterior pituitary to secrete adrenocorticotrophic hormone (ACTH). This stimulates the adrenal cortex to release corticosteroids. Secretion of CRH is controlled by: I Stressors acting on the hypothalamus -for example, trauma, pain, illness, infection, labour. I Circadian (24-hour) rhythm. With normal sleepwake patterns, CRH peaks around midnight, causing ACTH and corticosteroid hormones to peak in the early morning (6-9am). Disruption to the circadian cycle of corticosteroid secretion and adrenal suppression is minimised if oral corticosteroids are given in the morning, as a single dose before 9am, or on alternate days (CSM 1998). I Negative feedback control by circulating corticosteroids, endogenous or artificial, suppressing CRH and ACTH secretion. Corticosteroid drugs disrupt the regular feedback system and remove the normal stimulation to the adrenals. Eventually, the adrenals atrophy and are no longer able to increase hormone secretion in response to stress. Adrenal suppression shows individual variation, but may occur after two weeks' of oral, topical, inhaled or intranasal corticosteroids within the recommended dose range (Cave et al 1999) . However, in adults, clinical consequences are unlikely at doses below 2000µg/day for inhaled beclomethasone (Clark and Lipworth 1997) . Patients and professionals need to be alert for symptoms and signs of adrenal insufficiency, which include weakness, nausea, weight loss, hypoglycaemia, dehydration, electrolyte imbalance and hypotension.
There is some correlation between the severity of bruising and adrenal suppression. Therefore, detection of bruises should alert professionals to the need for investigations (Lipworth 1999) .
Adrenal crises arise when individuals with adrenal suppression and insufficiency are exposed to severe stress. The adrenals are unable to respond to stress in the usual way by secreting corticosteroids. The resulting medical emergency is characterised by nausea, vomiting, abdominal pain, exhaustion, dehydration, hypotension and shock. In severe cases, blood pressure falls rapidly; fatalities have occurred (BNF 2002) . To aid emergency admission, it is important that steroid cards be given to patients receiving corticosteroids for more than three weeks (CSM 1998), including those using high-dose inhalers 
Pharmacology (BNF 2002) . Adrenal crises may occur during therapy and for more than a year after discontinuation, as it may take this long for the adrenals to recover. To prevent adrenal crises, increased corticosteroid doses are often needed to enable patients to cope with illnesses or infections, and this can lead to dose escalation. Patients are particularly vulnerable if corticosteroids are discontinued abruptly and if regimens are changed to alternate-day therapy or from oral to topical routes.
If administration has continued for less than a week, problems with withdrawal are unlikely (BNF 2002) . Otherwise, doses should be gradually tapered to provide time for the adrenals to recover and resume hormone production (Karch 2000) . The rate of dose reduction will largely depend on disease control (CSM 1998) . Occasionally, problems occur when the route of administration is changed. Steroid withdrawal may be accompanied by: I Rebound of underlying disease. I Adrenal insufficiency. I Raised intracranial pressure, a rare complication. I Withdrawal syndrome characterised by fever, malaise, muscle and joint pains, runny nose, red eyes, and painful or itchy skin nodules. I Psychiatric withdrawal symptoms, mainly depression and fatigue, often unrelated to adrenal suppression. These are sometimes controlled by tricyclic antidepressants. Corticosteroid abuse and dependence may arise if individuals shun the effects of withdrawal or seek steroid-induced euphoria (Brown et al 1999) . Such patients are particularly vulnerable to adverse effects.
Before therapy is started, specific enquiries should be made regarding cautions and contraindications. Corticosteroids exacerbate several long-term conditions, such as diabetes mellitus, peptic ulcer disease, epilepsy, hypertension, congestive cardiac failure and mental illness (Abrams 1995) (Table 4) . Experts feel that corticosteroids are ill-advised for older people with diabetes (Hanlon et al 2001) or heart failure (Remme and Swedberg 2001) . Caution is advised in patients at risk of infection, as resistance is lowered, or with current infections, as signs and symptoms will be masked, allowing silent progression. Corticosteroids are contraindicated for patients with: I Systemic infections, particularly fungal infections, tuberculosis, measles or chickenpox, including recent exposure and illness -severe infection may result. I Eye infections, particularly herpes simplex -risk of corneal perforation with eye drops (BNF 2002) . I Hypersensitivity to corticosteroids. I Oesophagitis, gastritis or peptic ulcer -these conditions may progress silently, and clients may bleed without warning (McKenry and Salerno 1998). Pregnancy and breastfeeding The relative importance of disease control and adverse effects requires careful evaluation. Corticosteroids cross the placenta to a variable extent. Intrauterine growth retardation and reduced head circumference may occur if corticosteroids are administered for prolonged periods or short courses are repeated. Prednisolone (administered orally) passes into breast milk. Doses above 40mg/day may cause adverse effects in breastfed neonates, who should be carefully monitored (CSM 1998) . Topical corticosteroids should not be applied to the breasts of breastfeeding mothers (Jordan 2002) . Interactions The effects of corticosteroids are modified by co-administration with many drugs (Table 5) . Drugs such as carbamazepine and rifampicin, which increase the activity of liver enzymes, accelerate the elimination of corticosteroids, thereby decreasing their effectiveness. Other drugs, such as ketoconazole and erythromycin, inhibit liver enzymes, decreasing the elimination of corticosteroids and increasing adverse effects. Corticosteroids worsen many common disorders, such as hypertension and diabetes. The doses of medications prescribed to manage these conditions may therefore need to be increased (Stockley 1999) .
When initiating steroid therapy, certain 'baseline' observations will be needed: weight, blood pressure, heart rate, temperature, respiration rate and depth, assessment of peripheral perfusion, cognitive orientation and grip strength. A venous blood sample will also be needed to assess blood glucose, electrolyte balance and full blood count. Pre-existing infection should be investigated through enquiry and examination (Karch 2000) . Patients and families should be supplied with information leaflets, advice and, where appropriate, steroid cards. Many patients are concerned about the adverse effects of corticosteroids, particularly weight gain, infections, fractures, stunted growth and ocular complications, to the extent that more than one third would refuse any corticosteroid medication (Boulet 1998). Nurses
Medication management and patient monitoring Cautions and contraindications
Withdrawal of therapy
Consider how stress affects the normal regulation of the adrenals. What measurements would help the multidisciplinary team to recognise adrenal insufficiency? Would patients link symptoms of adrenal insufficiency with drug withdrawal? Do these symptoms resemble those of any other disease?
TIME OUT 5
Pharmacology need to explain the potential complications and adverse effects of corticosteroid medication, as well as the rationale for prescription. Some patients may require psychological or emotional support to cope with the effect of corticosteroids on body image.
The efficacy of prescribed corticosteroid regimens can be optimised by regular monitoring of the response to the drug, adverse effects (Table 6) , adherence to the prescribed regimen and the effectiveness of patient education. Some practitioners may formulate nursing diagnoses in relation to corticosteroid therapy, for example: I Altered cardiac output related to fluid retention. I Fluid volume excess related to water retention.
I Infection related to immunosuppression. I Ineffective individual coping related to body change and body image. I Knowledge deficit regarding drug therapy (McKenry and Salerno 1998) .
Inadequate treatment and follow-up remain important causes of preventable asthma deaths (Burr et al 1999) . However, corticosteroid use is complicated by numerous adverse drug reactions, both during therapy and following withdrawal; any of these may affect patient concordance. Apart from replacement Steroid-induced agitation and psychosis may be worsened, but withdrawal symptoms may be eased (Stockley 1999) 
